or Try an Advanced Search...

    Technical Analysis for CRDL - Cardiol Therapeutics Inc.

    Grade Last Price % Change Price Change
    B 2.62 1.95% 0.05
    CRDL closed up 1.95 percent on Friday, May 31, 2024, on 1.39 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical CRDL trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    New 52 Week High Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Older End-of-Day Signals for CRDL ...

       Recent Intraday Alerts

    Alert Time
    Gap Up Closed 2 days ago
    Down 1% 2 days ago
    Possible Pocket Pivot 2 days ago
    Gapped Up (Full) 2 days ago
    Rose Above Previous Day's High 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CRDL Chart by TradingView
    Basic chart:

    Profile

    Cardiol Therapeutics Inc. Description

    Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Disease Clinical Research Heart Failure Orphan Drug Heart Disease Cannabidiol

    Is CRDL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 2 Cardiol Therapeutics Announces Year-End 2023 Update on Operations
    Feb 21 Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Feb 15 Cardiol stock rallies 28% on FDA orphan drug status for CardiolRx
    Feb 15 Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
    Jan 9 Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
    Dec 5 Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
    See more CRDL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.66
    52 Week Low 0.66
    Average Volume 339,274
    200-Day Moving Average 1.28
    50-Day Moving Average 1.98
    20-Day Moving Average 2.23
    10-Day Moving Average 2.33
    Average True Range 0.15
    RSI (14) 73.26
    ADX 36.25
    +DI 29.83
    -DI 8.33
    Chandelier Exit (Long, 3 ATRs) 2.20
    Chandelier Exit (Short, 3 ATRs) 2.35
    Upper Bollinger Bands 2.58
    Lower Bollinger Band 1.89
    Percent B (%b) 1.06
    BandWidth 30.74
    MACD Line 0.15
    MACD Signal Line 0.13
    MACD Histogram 0.0283
    Fundamentals Value
    Market Cap 170.6 Million
    Num Shares 65.1 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -8.19
    Price-to-Sales 1069.35
    Price-to-Book 2.71
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.83
    Resistance 3 (R3) 2.82 2.74 2.80
    Resistance 2 (R2) 2.74 2.69 2.75 2.78
    Resistance 1 (R1) 2.68 2.65 2.64 2.69 2.77
    Pivot Point 2.60 2.60 2.58 2.61 2.60
    Support 1 (S1) 2.54 2.55 2.50 2.55 2.47
    Support 2 (S2) 2.46 2.51 2.47 2.46
    Support 3 (S3) 2.40 2.46 2.45
    Support 4 (S4) 2.41